Dr. Mu's Upcoming and Past News and Activities
7/1/2021: Member of the NCI Study Section Meeting for Research Specialist Award (R50), a virtual meeting.
6/24-25/2021: Member of the NCI Study Section Meeting for Research Specialist Award (R50), a virtual meeting.
3/22-23/2021: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT), a virtual meeting.
3/11/2021: Member of NCI Study Section Meeting for Omnibus R03 and Clinical and Translational Exploratory/Developmental Studies (R21), a virtual meeting.
11/19-20/2020: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT), a virtual meeting.
September 8, 2020: Dr. Mu was appointed the Director of Medical Student Research Opportunities, EVMS.
7/1-2/2020: Member of the NCI Special Emphasis Panel for the Clinical and Translational R21 and Omnibus R03, a virtual meeting.
6/25-26/2020: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT), a virtual meeting.
3/23-24/2020: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT), a virtual meeting.
2/12-13/2020: Member of the NCI Special Emphasis Panel for the Clinical and Translational R21 and Omnibus R03 in Bethesda, MD.
11/14-15/2019: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT) in Washington, DC.
October/2019: Grant reviewer for the James and Esther King Biomedical Research Program, Florida Department of Health.
6/17-18/2019: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT) in Chicago, IL.
5/20/2019: Member of the NIH Study Section on the US-China Program for Biomedical Collaborative Research, Bethesda, MD.
3/18-19/2019: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT) in Bethesda, MD.
11/15-16/2018: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT) in San Francisco, CA.
6/18-19/2018: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT) in Bethesda, MD.
3/23/2018: Member of the NIH Study Section meeting on the Cancer Research Workforce Diversity, Washington DC.
11-12/2017: Grant reviewer for the Biomedical Research Programs of the Florida Department of Health.
9/11/2017: Seminar Speaker at the Four Diamonds Pediatric Cancer Research Center at Pennsylvania State University. Seminar title: Gene-dependent alteration of cancer secretome and metabolism.
6/22-23/2017: Member of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT) in Bethesda, MD.
3/1/2017: Speaker, American Chemical Society (ACS) Chemistry for Life seminar series, "Cellular Secretome and Cancer Biology", Christopher Newport University, Newport News, VA.
11/17-18/2016: Co-Chair of the NIH Cancer Drug Development and Therapeutics Study Section meeting (CDDT) in San Francisco, CA.
10/10/2016: Seminar Speaker, Dept of Biochemistry and Molecular Biology, Penn State University, Hershey, PA. Seminar Title: The Odyssey of Cancer Gene Amplification Research.
6/14-15/2016: Co-Chair of the NIH Cancer Drug Development and Therapeutics Study Section member (CDDT), IAM.
3/24-25/2016: NIH Cancer Drug Development and Therapeutics Study Section member (CDDT, 2016/05 ZRG1 OTC-T (10) B) in Bethesda, MD.
3/3-4/2016: NCI Special Emphasis Panel/Scientific Review Group member, ZCA1 SRB-1 (M1), Bethesda, MD.
2/19/2016: Dr. Mu presented a seminar "The Odyssey of Cancer Gene Amplification Research" at the Dept of Biology, Hampton University.
11/16-17/2015: NIH Cancer Drug Development and Therapeutics (CDDT) Study Section Meeting in San Francisco, CA.
11/12-13/2015: NCI Cancer Health Disparities Special Emphasis Panel review meeting (2016/01 ZRG1 OBT‐K (55)) at Bethesda, MD.
6/29-30/2015: NIH Special Emphasis Panel/Scientific Review Group, 2015/10 ZCA1 SRB-1 (O1) 2, Washington DC.
6/9-10/2015: Co-Chair of the NCI Cancer Drug Development and Therapeutics (CDDT) Study Section Meeting (IAM).
3/16-17/2015: Member of the NCI Cancer Drug Development and Therapeutics (CDDT) Study Section Meeting in Washington DC.
1/2015: Dr. Mu joined the Editorial Board of Current Cancer Drug Target.
11/4-5/2014: NIH Special Emphasis Panel/Scientific Review Group, 2015/01 ZCA1 SRB‐1 (J1) R, Washington DC.
7/30/2014: Dr. Mu received funding support from the EVMS Professional Enrichment and Growth Grant mechanism.
7/1/2014: Dr. Mu was appointed to chair the Dean's Standing Research Advisory Committee (RAC).
7/1-2/2014: NIH Special Emphasis Panel, ZCA1 SRLB-1, NCI omnibus R21/R03 FOA, Washington DC.
6/2014: Dr. Mu was appointed a member of the EVMS Dermatology Chair Search Committee and the EVMS Student's Disability Committee.
6/17-18/2014: Co-chair of the NCI study section on Cancer Drug Development & Therapeutics (CDDT, 2014/10 ZRG1 OTC-T (10) B).
4/17-18/2014: Reviewer, NIH Cancer Health Disparities/Diversity in Basic Cancer Research study section, Washington DC.
3/17-18/2014: Member, Study Section, NCI Small Business: Cancer Drug Development & Therapeutics, Washington DC.
3/6-7/2014: NIH Special Emphasis Panel, ZCA1 SRLB-1 (M1), NCI omnibus R21/R03 FOA, Washington DC.
2/4/2014: Departmental seminar series, Dept of Biochemistry & Biophysics, UNC at Chapel Hill, “Lung cancer, microRNAs, & cholesterol”.
11/14-15/2013: Member, Study Section, NCI Small Business: Cancer Drug Development & Therapeutics, San Antonio, TX.
11/11/2013: Seminar, Dept of Physiological Sciences, EVMS, Norfolk, VA. “Connecting a lung adenocarcinoma marker to cholesterol metabolism”.
10/8/2013: Seminar, Frank Reidy Research Center for Bioelectrics, ODU, Norfolk, VA. “Discovery of an amplified lung cancer gene & its connections to microRNAs”
9/20/2013: Seminar, Dept of Biological Sciences, ODU, Norfolk, VA. “MicroRNAs & A Bifunctional Lung Cancer Gene”.
7/1/13: Dr. Mu was profiled in the Journal of Biological Chemistry.
6/18-19/2013: Co-Chair, Study Section, NCI Small Business: Cancer Drug Development & Therapeutics
5/3/2013: Research panelist, VABio annual meeting, Charlottesville, VA